Empagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Empagliflozin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
877
Registered trials
363
Result records
5
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Empagliflozin can convert its Small molecule drug profile and SGLT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Empagliflozin (query alias: empagliflozin) |
|---|---|
| Modality / target | Small molecule drug; SGLT2; SGLT2 inhibitors |
| Highest global status | Approved |
| Originator | Boehringer Ingelheim GmbH |
| Active developers | Boehringer Ingelheim GmbH, University of Utah, National Institute of Diabetes & Digestive & Kidney Diseases |
The MCP disease footprint includes Cardiovascular Diseases, Heart failure with normal ejection fraction, Heart failure with reduced ejection fraction. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600127726 | Phase 4 | Recruiting | 75 | Matrix Metalloproteinase-9(MMP-9) |
| NCT07700940 | Phase 4 | Recruiting | 66 | Urinary protein-creatinine ratio (UPCR) |
| NCT07692256 | Phase 2 | Recruiting | 60 | serum Brain Natriuretic Peptide (BNP) in pg/mL |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
26-PUB: Real-World Preference for Triple Fixed-Dose Combination of Empagliflozin, Sitagliptin, and Metformin by Various Health Care Specialist in India: Real Impossible Trio
Not Applicable; n=2290; evaluation: Positive. Reported fields: Dose = 47.25 % ; Dose = 52.75 %
1840-P: Urogenital Infection Risk of Individual Sodium–Glucose Cotransporter 2 Inhibitors
Not Applicable; n=1612340; evaluation: Positive. Reported fields: Genital tract infection: HR = 0.99(95.0% CI, 0.97 - 1.0); Genital tract infection: HR = 0.99(95.0% CI, 0.97 - 1.0)
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial
Phase 2; n=92; evaluation: Negative. Reported fields: IL-6: ETR = 1.03(95.0% CI, 0.82 - 1.3), P-Value = 0.78; IL-6: ETR = 1.03(95.0% CI, 0.82 - 1.3), P-Value = 0.78
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Empagliflozin addresses Cardiovascular Diseases, Heart failure with normal ejection fraction, Heart failure with reduced ejection fraction. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-12-14 | Torrent Pharma inks pact with Boehringer Ingelheim to co-market anti-diabetic drug in India | Approved | Financial terms not disclosed |
| 2022-03-01 | BI and Eli Lilly will collaborate on a phase III EMPULSE trial to investigate the impact of Jardiance on adult patients with acute heart failure. | Phase 3 | Financial terms not disclosed |
| 2020-06-29 | Cipla and Boehringer collaborate to jointly market Oboravo, Oboravo Met, and Tiptengio for the treatment of type-II diabetes in India. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pharmaceutical composition of GLP-1r agonist and empagliflozin and use”. The milestone feed surfaced a patent-application signal described as “Application of baicalin as SGLT2 inhibitor in treatment of diabetic heart failure”. The milestone feed surfaced a patent-application signal described as “Medical use of combination of endothelin a (ETA) receptor antagonist and SGLT-2 inhibitor”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
